RECRUITINGOBSERVATIONAL
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
About This Trial
This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).
Who May Be Eligible (Plain English)
Who May Qualify:
- Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site.
- Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan
- The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking.
- Provides written willing to sign a consent form (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited)
Who Should NOT Join This Trial:
- Less than 18 years of age
- Minimum image dataset is not available
- Image dataset is not in a compatible format
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site.
* Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan
* The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking.
* Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited)
Exclusion Criteria:
* Less than 18 years of age
* Minimum image dataset is not available
* Image dataset is not in a compatible format
Locations (5)
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
The Austin Hospital
Melbourne, Victoria, Australia